Positive Outlook Boosted Gilead Sciences (GILD) in Q1

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. US large-cap equity fell in the quarter following the uncertainty surrounding US tariffs. In the first quarter of 2025, the fund underperformed the Russell 1000 benchmark. Negative stock selection and lack of energy exposure led to the underperformance of the fund in the quarter. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its first-quarter 2025 investor letter, Impax US Sustainable Economy Fund highlighted stocks such as Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company.  The one-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was 11.06%, and its shares gained 70.66% of their value over the last 52 weeks. On June 4, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) stock closed at $109.02 per share with a market capitalization of $135.613 billion.

Impax US Sustainable Economy Fund stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q1 2025 investor letter:

“Gilead Sciences, Inc. (NASDAQ:GILD) (Health Care) the company is owned due to its role in solving evolving heath care challenges through the development of new medical treatments for conditions as chronic diseases are on the rise. The company also has one of the highest systematic ESG scores in the portfolio. Gilead reported better-than-expected quarterly results, largely driven by strong revenue from its HIV franchise. The company also provided an optimistic earnings guidance for the next fiscal year, helping provide defensiveness amid a flurry of volatility.”

Is Gilead Sciences, Inc. (GILD) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

A physician and a patient having a discussion in a hospital about biopharmaceutical medicines.

Gilead Sciences, Inc. (NASDAQ:GILD) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 79 hedge fund portfolios held Gilead Sciences, Inc. (NASDAQ:GILD) at the end of the first quarter, which was 74 in the previous quarter. While we acknowledge the potential of Gilead Sciences, Inc. (NASDAQ:GILD) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.

In another article, we covered Gilead Sciences, Inc. (NASDAQ:GILD) and shared the list of best unstoppable stocks that pay dividends. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.